Stereotactic Body Radiation and Stereotactic Ablative Radiotherapy Therapy for Cancers
Language: English
Published by MDPI AG, 2025
- Hardcover
- New

Condition: New
US$ 101.90
Quantity: 2 available
Add to basketItem description from seller
Within the last decade, the radiation oncology community has witnessed increased adoption of hypo-fractionated, high-precision radiation therapy using stereotactic body radiation therapy (SBRT), also referred to as stereotactic ablative radiotherapy (SABR), across many disease sites in the thorax, abdomen, and pelvis on the basis of clinical evidence demonstrating both efficacy and safety. The indication of SBRT/SABR is poised to greatly expand in coming years especially for the management of oligometastatic and oligoprogressive disease. Technological advancements in precision patient alignment, in-room imaging, tumor motion management, and treatment machine deliveries have also expanded the feasibility of delivering ablative radiation doses while better sparing nearby critical organs, thus markedly enhancing the therapeutic ratio.Therefore, this Special Issue aims to include articles on all types of stereotactic modalities and treatments (SBRT, SABR, and others) using ultra-hypofractionated and hypofractionated high-dose-per-fraction regimens, including original research describing clinical outcomes and also describing novel treatment planning and delivery approaches. Sprache: Englisch Gewicht in Gramm: 628.…
Seller Inventory # IB-14695727
- Title
- Stereotactic Body Radiation and Stereotactic Ablative Radiotherapy Therapy for Cancers
- Publisher
- MDPI AG
- Publication year
- 2025
- Condition
- Neu
- Binding
- Gebundene Ausgabe
- Language
- English
- ISBN 10
- 3725835748
- ISBN 13
- 9783725835744
- Item weight
- 628 grams
Within the last decade, the radiation oncology community has witnessed increased adoption of hypo-fractionated, high-precision radiation therapy using stereotactic body radiation therapy (SBRT), also referred to as stereotactic ablative radiotherapy (SABR), across many disease sites in the thorax, abdomen, and pelvis on the basis of clinical evidence demonstrating both efficacy and safety. The indication of SBRT/SABR is poised to greatly expand in coming years especially for the management of oligometastatic and oligoprogressive disease. Technological advancements in precision patient alignment, in-room imaging, tumor motion management, and treatment machine deliveries have also expanded the feasibility of delivering ablative radiation doses while better sparing nearby critical organs, thus markedly enhancing the therapeutic ratio.
Therefore, this Special Issue aims to include articles on all types of stereotactic modalities and treatments (SBRT, SABR, and others) using ultra-hypofractionated and hypofractionated high-dose-per-fraction regimens, including original research describing clinical outcomes and also describing novel treatment planning and delivery approaches.
"Synopsis" may belong to another edition of this title.
Shipping rates from Germany to U.S.A.
| Item | 10 to 12 business days | 8 to 10 business days |
|---|---|---|
| First item | US$ 54.85 | US$ 82.45 |
Payment methods
- Check